GNTA

Genenta Science (GNTA)

About Genenta Science (GNTA)

Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.

Details

Daily high

$2.04

Daily low

$1.75

Price at open

$1.84

52 Week High

$10.00

52 Week Low

$0.55

Market cap

39.4M

Dividend yield

0.00%

Volume

399,795

Avg. volume

4.6M

P/E ratio

-4.52

Genenta Science News